nab-Paclitaxel for the treatment of pancreatic cancer.

ABSTRACT:

Background

Nanoparticle albumin-bound paclitaxel (nab-P) plus gemcitabine (Gem) became a standard treatment option for metastatic pancreatic cancer (MPC) following positive results from a global phase III trial (MPACT). A large number of studies have now published results on the use of nab-P/Gem to treat advanced and early-stage disease, warranting a comprehensive review. The main goal of this systematic review is to summarize the efficacy and safety data of nab-P/Gem for the treatment of pancreatic cancer (PC).

Methods

This systematic review includes results from studies that either published results in a peer-reviewed journal or presented the results at a major oncology conference.

Results

Sixty-two studies were included (50 in the advanced/meta

SUBMITTER: Kim G 

PROVIDER: S-EPMC5360414 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature